<DOC>
	<DOCNO>NCT01727154</DOCNO>
	<brief_summary>The purpose study evaluate immune response induce sipuleucel-T ( Provenge® ) .</brief_summary>
	<brief_title>Immune Monitoring Protocol Men With Prostate Cancer Enrolled Clinical Trial Sipuleucel-T</brief_title>
	<detailed_description>Subjects receive sipuleucel-T , potentially medication , part clinical trial concurrently enrol . For study , cellular humoral immune response assess . No additional study treatment conduct beyond require subject 's concurrent clinical trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subjects must least 18 year age Subjects prostate cancer enrol clinical trial sipuleucelT ( include Dendreonsponsored clinical trial registry , IIT ) Subjects yet undergone leukapheresis first dose sipuleucelT Subjects must understand sign inform consent form prior first leukapheresis •None</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>